

## ***Adolescent Depression Remission/Response***

### **Measure Description**

Percentage of patients 12 to 17 years of age with the diagnosis of major depression or dysthymia and an initial PHQ-9 or PHQ-A score greater than 9 who achieved remission or response within four to eight months.

### **Measure Components**

<b>Numerator Statement</b>	<p>Numerator 1: Patients who achieved remission within four to eight months from the initial PHQ-9 or PHQ-A score &gt; 9, defined as a PHQ-9 or PHQ-A score less than 5</p> <p>Numerator 2: Patients who achieved response within four to eight months from the initial PHQ-9 or PHQ-A score &gt; 9, defined as a decrease in PHQ-9 or PHQ-A score of 50% or more</p>
<b>Denominator Statement</b>	Patients 12 to 17 years of age with a diagnosis of major depression or dysthymia and an initial PHQ-9 or PHQ-A score greater than 9
<b>Exclusions</b>	Patients with a diagnosis of bipolar disorder, psychotic disorder, autism spectrum disorder, or personality disorder at any time during the measurement period

### **Measure Definitions**

<b>Intake Period</b>	January 1 through December 31 of the year immediately prior to the measurement year.
<b>Measurement Period</b>	January 1 through December 31 of the measurement year.
<b>Initial depression-related PHQ-9 score greater than 9</b>	The initial PHQ-9 or PHQ-A score greater than 9 is the earliest occurrence of a PHQ-9 or PHQ-A score greater than 9 associated with a depression-related patient contact that occurs during the intake period. PHQ scores that are either a) less than or equal to 9 or b) not associated with a depression-related patient contact during the intake period are not eligible.
<b>Standardized Tool</b>	<p>An assessment tool that has been appropriately normalized and validated for the population in which it is used. For this measure, symptom assessment tools include:</p> <ul style="list-style-type: none"> <li>• Patient Health Questionnaire (PHQ-9)</li> <li>• Patient Health Questionnaire for Adolescents (PHQ-A)</li> </ul>
<b>Patient contact</b>	A contact between patient and provider can be face-to-face, phone-based, or via secure messaging (e.g., email or patient portal).
<b>Remission</b>	Remission is defined as a PHQ-9 or PHQ-A score less than 5 within 4 to 8 months of the index episode start date.

<b>Response</b>	<p>Response is defined as a 50% or greater reduction in PHQ-9 or PHQ-A score in patients who had an initial depression-related PHQ-9 or PHQ-A score greater than 9. The condition of PHQ-9 or PHQ-A score response is met when the following is true:</p> <p>Follow up PHQ-9 or PHQ-A score (within four to eight months) <math>\leq</math> [initial PHQ-9 or PHQ-A score divided by 2]</p>
-----------------	---

<b>Specification</b>	
<b>Measure Dimension</b>	<b>Specification</b>
<b>Denominator</b>	<p>Patients 12 to 17 years of age with a depression-related PHQ-9 or PHQ-A score greater than 9 that occurred +/- 30 days of a depression-related patient contact during the intake period.</p> <ul style="list-style-type: none"> <li>• Age is calculated at the start of the intake period.</li> <li>• A depression-related condition is defined by any of the following that is documented as the reason for a contact with the patient: Major Depressive Disorder or Dysthymia.</li> </ul>
<b>Numerator 1 (Remission)</b>	Patients who achieved remission within four to eight months from the initial PHQ-9 or PHQ-A score > 9, defined as a PHQ score less than 5.
<b>Numerator 2 (Response)</b>	Patients who achieved response within four to eight months from the initial PHQ-9 or PHQ-A score > 9, defined as a decrease in PHQ-9 or PHQ-A score of 50% or more.
<b>Denominator Exclusions</b>	Patients with a diagnosis of bipolar disorder, psychotic disorder, autism spectrum, or personality disorder at any time during the measurement period or intake period.

These Measures were developed and are owned by the National Committee for Quality Assurance (NCQA). The work was funded by the Agency for Healthcare Research and Quality (AHRQ) and the Centers for Medicare & Medicaid Services (CMS) under the CHIPRA Pediatric Quality Measures Program Centers of Excellence grant number U18 HS020503-03. AHRQ, in accordance to CHIPRA 42 U.S.C. Section 1139A(b), and consistent with AHRQ's mandate to disseminate research results, 42 U.S.C. Section 299c-3, has a worldwide irrevocable license to use and permit others to use products and materials from the grant for government purposes which may include making the materials available for verification or replication by other researchers, the health care community and the public if such distribution would significantly increase access to a product and thereby produce substantial or valuable public health benefits.

Neither NCQA nor their members shall be responsible for any use of the Measures. They are not clinical guidelines and do not establish a standard of medical care. NCQA makes no representations, warranties or endorsement about the quality of any organization or physician that uses or reports performance measures, and NCQA has no liability to anyone who relies on such measures. NCQA holds a copyright in these Measures and can rescind or alter these Measures at any time. Users of the Measures shall not have the right to alter, enhance or otherwise modify the Measures. The Measures can be reproduced and distributed, without modification, for noncommercial purposes, e.g., use by health care providers in connection with their practices. "Commercial use" is defined as the sale,

license, or distribution of the Measures for commercial gain, or incorporation of the Measures into a product or service that is sold, licensed or distributed for commercial gain, even if there is no actual charge for inclusion of the Measure. All commercial uses must be approved by NCQA and are subject to a license at the discretion of NCQA. © 2015 by the National Committee for Quality Assurance.